Symbol | Exchange | Currency |
|---|
(Reuters) - Gilead Sciences (NASDAQ:GILD) will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics (NASDAQ:JNCE) for $67 million,...
(Reuters) - Gilead Sciences (NASDAQ:GILD) will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics (NASDAQ:JNCE) for $67 million,...
We expect investors to focus on pipeline updates when Jounce Therapeutics, Inc. (NASDAQ:JNCE) reports fourth-quarter 2019 results.Shares of the company have gained 43.7% in the...
ImmunoGen, Inc. (NASDAQ:IMGN) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares...
The U.S. economy has witnessed several ups and downs this year. While weak global economic growth outlook weighed on the stocks, federal measures like rate cuts boosted the...
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. The Company has developed a suite of integrated technologies that consist of its Translational Science Platform, enabling it to interrogate the cellular and molecular composition of tumors. Its program, JTX-8064, is a humanized IgG4, anti-LILRB2 monoclonal antibody designed to reprogram macrophages. JTX-8064 is being developed for patients with either PD-(L)1-inhibitor resistant or PD-(L)1 inhibitor-sensitive tumors. Vopratelimab is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS). Pimivalimab is a clinical-stage anti-PD-1 monoclonal antibody that is being developed primarily for its use in combination with its product candidates.
| Average | 6.000 (+395.868% Upside) |
| High | 11.000 |
| Low | 3.000 |
| Price | 1.210 |
| No. of Analysts | 5 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Buy | Buy | Buy | Strong Sell |
| Technical Indicators | Sell | Strong Sell | Strong Buy | Strong Buy | Strong Sell |
| Summary | Sell | Neutral | Strong Buy | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 150.82 | 151.18 | 148.17 | +5.39 | +3.71% | 101.39M | NASDAQ | |||
| 112.91 | 114.00 | 108.88 | +7.76 | +7.38% | 142.72M | NASDAQ | |||
| 53.70 | 54.00 | 53.70 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 25.81 | 25.89 | 25.49 | +0.13 | +0.51% | 4.61M | NYSE | |||
| 188.27 | 196.75 | 182.61 | +6.86 | +3.78% | 214.41M | NASDAQ | |||
| 264.60 | 264.69 | 257.25 | +11.85 | +4.69% | 39.04M | NASDAQ | |||
| 107.74 | 107.85 | 105.61 | +7.31 | +7.28% | 65.06M | NASDAQ | |||
| 188.77 | 197.16 | 180.16 | +35.65 | +23.28% | 149.57M | NASDAQ | |||
| 88.41 | 89.97 | 86.22 | +4.51 | +5.38% | 13.23M | NYSE | |||
| 73.07 | 74.20 | 72.68 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 217.09 | 219.49 | 207.00 | +7.66 | +3.66% | 55.78M | NASDAQ | |||
| 37.05 | 37.97 | 36.82 | -0.67 | -1.78% | 862.76K | NYSE | |||
| 40.59 | 41.01 | 40.52 | -0.13 | -0.32% | 3.43M | NYSE | |||
| 0.127 | 0.139 | 0.123 | -0.004 | -3.27% | 4.08M | OTC Markets | |||
| 8.03 | 8.39 | 7.90 | -0.10 | -1.23% | 8.52M | NYSE |